| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
The U.S. Food and Drug Administration (FDA) can do a lot to spur action and interest (or concern) in certain areas. And artificial intelligence (AI) may be one of those areas, given an online posting late last year by FDA Commissioner Dr. Scott Gottlieb in which he noted, “Our longstanding goal for medical care is to ensure that the right drug or device is delivered to the right patient at the right time. This vision is increasingly possible with the innovative products that are becoming available. These new technologies offer transformative opportunities, but they also challenge [FDA] to modernize its approach to evaluating new innovations.”
 
And now, it seems, the FDA seeks to promote enhanced innovation in multiple areas that currently lack regulatory standards—one of those being AI. Given that this is happening concurrently with FDA efforts to improve clinical trial efficiency, one could logically assume there will be overlap between the two areas, and the FDA commissioner’s further comments hint at that.
 
“AI holds enormous promise for the future of medicine. We’re actively developing a new regulatory framework to promote innovation in this space and support the use of AI-based technologies,” Gottlieb noted. “We know that to support the widespread adoption of AI tools, we need patients and providers to understand the connection between decision-making in traditional healthcare settings and the use of these advanced technologies.”
 
Of course, it’s not just the government interested in the intersection of clinical trials and AI. For example, the company Trials.ai is leveraging artificial intelligence and machine learning technology to optimize clinical trials for speed and success.
 
And last year, IBM’s Watson cognitive computing system—which first gained fame by defeating all-star contestants on the game show “Jeopardy!” several years ago, and has since found its way into a variety of healthcare and life-science applications—got teamed up with the Mayo Clinic.
 
In this pilot collaboration, which is also a proof-of-concept study, IBM and the Mayo Clinic are applying a customized version of Watson to the task of matching patients more quickly with appropriate clinical trials, beginning with cancer.
 
“In an area like cancer—where time is of the essence—the speed and accuracy that Watson offers will allow us to develop an individualized treatment plan more efficiently, so we can deliver exactly the care that the patient needs,” said Dr. Steven R. Alberts, chair of Medical Oncology at the Mayo Clinic Cancer Center.
 
One of the hopes is that use of AI for trial matching will clear up bottlenecks in recruitment and get more people involved in trials who might otherwise fall through the cracks.

About the Author

Related Topics

Published In

Volume 15 - Issue 2 | February 2019

February 2019

February 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue